Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction

  1. Deborah Grady, MD, MPH; and
  2. Eric Vittinghoff, PhD
  1. University of California, San Francisco; San Francisco Veterans Affairs Medical Center (Grady, Vittinghoff)

    The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

    •Include no more than 300 words of text, three authors, and five references

    •Type with double-spacing

    •Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

    Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

    Annals welcomes electronically submitted letters.

    IN RESPONSE:

    We thank Drs. Peverill, Waitkevicz and Axelrod, and Goldstein for their comments on our manuscript.

    We found an error in the manuscript after publication. Rates of venous thromboembolic events in the first 90 days after lower-extremity fracture and myocardial infarction were mislabeled as numbers of events per 100 women. In fact, the cited values were rates per 100 woman-years. Since the at-risk period was only 90 days or 0.25 year, the number of events per 100 women in the first 90 days after lower-extremity fracture is 23 (the rate per 100 woman-years cited in our paper) × 0.25 = 5.8 venous thromboembolic events per 100 women in the first 90 days after fracture. A similar mistake was made in reporting the number of events per 100 women in the first 90 days after myocardial infarction; the correct number is 2.5 venous thromboembolic events per 100 women. We regret our error.

    Deborah Grady, MD, MPH

    Eric Vittinghoff, PhD

    University of California, San Francisco; San Francisco Veterans Affairs Medical Center; San Francisco, CA 94121

    « Previous | Next Article »Table of Contents

    Navigate This Article

    1. Top